CellSearch (Veridex) is an FDA-approved technique using EpCAM coated beads to isolate CTCs from blood but this surface marker selection is limited to carcinomas that expresses EpCAM [104], and currently, this technique is only approved for prognostic evaluation of metastatic breast, prostate, lung and colon cancer. The gene discussed is EPCAM; the disease is carcinoma.